Economics Of Personalizing Breast Cancer Treatment
 

Cost-utility analyses of new biotechnologies are often conducted under best-practice hypotheses; there exists a need to examine the robustness of these analyses in the real-health practice setting. Oncotype DX® (Genomic Health, Inc...

More...